456 Studies Now Enrolling
A Phase I, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection to patients with advanced/metastatic solid tumors or lymphomas
Study of MIW815 (ADU-S100) in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
| Sponsor: | Novartis and Aduro Biotech |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR6676 |
| U.S. Govt. ID: | NCT02675439 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to learn more about the study drug, MIW815 (ADU-S100). The study will identify the dose that can safely be given to people with solid tumors or lymphomas. The study will also see how well MIW815 (ADU-S100) works in people treated.
This study is closed
Do You Qualify?
| Do you have a confirmed solid tumor or lymphoma? | Yes | No |
| Have you had treatment for your disease before? Or, is there not a standard treatment available for your disease? | Yes | No |
| Does your cancer continue to grow? | Yes | No |
| Are you willing to have additional biopsies while on study? | Yes | No |